Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.
The Food and Drug Administration approved Eli Lilly's blockbuster weightloss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is ...
which had Zepbound approved as a weight-loss drug last year. A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis on April 26, ... [+] 2017. Zepbound, an Eli ...